Synthesis and Pharmacological Evaluation of 1-Oxo-2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinolines and Related Analogues as a New Class of Specific Bradycardic Agents Possessing If Channel Inhibitory Activity

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4728-4740

  Kubota, Hideki ^a   Kakefuda, Akio ^a   Watanabe, Toshihiro ^a   Ishii, Noe ^a   Wada, Koichi ^a   Masuda, Noriyuki ^a   Sakamoto, Shuichi ^a   Tsukamoto, Shin ichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 [1 [3 (3,4 METHYLENEDIOXYPHENOXY)PROPYL] 3 PIPERIDYL] 1 OXO 1,2,3,4 TETRAHYDROISOQUINOLINE; ION CHANNEL; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GUINEA PIG; HEART RIGHT ATRIUM; IC 50; ION CURRENT; MALE; NONHUMAN; PACEMAKER; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD PRESSURE; DEPRESSION, CHEMICAL; GUINEA PIGS; HEART ATRIA; HEART RATE; ION CHANNELS; ISOQUINOLINES; MALE; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERIDINES; RATS; RATS, WISTAR; SINOATRIAL NODE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142028920     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0301742     Document Type: Article

References (26)

1. Yamakawa, H.; Takeuchi, M.; Takaoka, H.; Hata, K.; Mori, M.; Yokoyama, M. Negative chronotropic effect of β-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. Circulation 1996, 94, 340-345.
2. Kannel, W. B.; Kannel, C.; Paffenbarger, R. S., Jr.; Cupples, A. Heart rate and cardiovascular mortality: The Framingham study. Am. Heart J. 1987, 113, 1489-1494.
3. Shaper, A. G.; Wannamethee, G.; Macfarlane, P. W.; Walker, M. Heart rate, ischemic heart disease, and sudden cardiac death in middle-aged British men. Br. Heart J. 1993, 70, 49-55.
4. Platini, P.; Julius, S. Heart rate and the cardiovascular risk. J. Hypertension 1997, 15, 3-17.
5. Platini, P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality. Drugs 1999, 57 (5), 713-724.
6. Opie, L. H. Pharmacology of acute effort angina. Cradiovasc. Drugs Ther. 1989, 3, 257-270.
7. Kern, M. J.; Deligonul, U.; Labovitz, A. Influence of drug therapy on the ischemic response to acute coronary occlusion in man: Supply side economics. Am. Heart J. 1989, 118, 361-380.
8. Kobinger, W.; Lilie, C. Specific bradycardic agents-a novel pharmacological class? Eur. Heart J. 1987, 8 (Suppl. L), 7-15.
9. Kobinger, W.; Lillie, C. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylamino]propyl]-2H-3-benzazepin-2-one hydrochloride, "a new specific bradycardic agent". Eur. J. Pharmacol. 1984, 104, 9-18.
10. Reiffen, M.; Eberlein, W.; Muller, P.; Psior, M.; Noll, K.; Heider, J.; Lillie, C.; Kobinger, W.; Luger, P. Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties. J. Med. Chem. 1990, 33, 1496-1504.
11. f in rabbit sinoatrial node cells by zatebradine (UL-FS 49). Circulation 1993, 88, 2389-2401.
12. Gardiner, S. M.; Kemp, P. A.; March, J. E.; Bennett, T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S-16257, in conscious rats. Br. J. Pharmacol. 1995, 115, 579-586.
13. Bois, P.; Bescond, J.; renaudon, B.; Lenfant, J. Mode of action of bradycardic agent, S-16257, on ionic currents of rabbit sinoatrial node cells. Br. J. Pharmacol. 1996, 118, 1051-1057.
14. Thollon, C.; Bidouard, J. P.; Cambarrat, C.; Lesage, J.; Reure, H.; Delescluse, I.; Vian, J.; Peglion, J. L.; Vilaine, J. P. Stereospecific in vitro and in vivo effects of the new sinos node inhibitor (+)-S-16257. Eur. J. Pharmacol. 1997, 339, 43-51.
15. Baiker, W.; Czako, E. V.; Keck, M.; Nehmiz, G. Efficacy and duration of action three doses of Zatebradine (UL-FS 49CL) in patients with chronic angina pectoris compared to placebo. Hjalmarson, A., Remme, W. J., Eds. In Sinus node inhibitors; Springer-Verlag: New York, 1991; pp 55-63.
16. Ragueneau, I.; Laveille, C.; Jochemsen, R.; Resplandy, G.; Funck-Brentano, C.; Jaillon, P. Pharmacokinetic-pharmacodynamic modeling of the effects of Ivabradine, a direct sinos node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol. Ther. 1998, 64, 192-203.
17. Kubota, H.; Kakefuda, A.; Watanabe, T.; Taguchi, Y.; Ishii, N.; Masuda, N.; Sakamoto, S.; Tsukamoto, S. (± )-2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinolines as a New Class of Specific Bradycardic Agents. Bioorg. Med. Chem. Lett. 2003, 13, 2155-2158.
18. Kobinger, W.; Lillie, L. AQ-A 39 (5,6-dimethoxy-2(3{[2-(3,4-dimethoxy)phenylethyl]methylamino}propyl) phthalimidine), a specific bradycardic agent with direct action on the heart. Eur. J. Pharmacol. 1981, 72, 153-164.
19. Berne, R. M.; Levy, M. N. The Arterial System. In Cardiovascular Physiology, 6th ed.; Mosby-Year Book, Inc.: St. Louis, 1992; pp 135-151.
20. Banwell, M. G.; Bissett, B. D.; Busato, S.; Cowden, C. J.; Hockless, D. C. R.; Holman, J. W.; Read, R. W.; Wu, A. W. Trifluoromethanesulfonic anhydride-4-(N,N-dimethylamino)pyridine as a reagent combination for effecting Bischler-Napieralski cyclization under mild conditions: Application to the total synthesis of the Amaryllidaceae alkaloids N-Methylcrinasiadine, Anhydrolycorinone, Hippadine and Oxoassoanine. J. Chem. Soc., Chem. Commun. 1995, 2551-2553.
21. de Costa, B. R.; Dominguez, C.; He, X.; Williams, W.; Radesca, L.; Bowen, W. Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)-ethyl]-N-methylethylenediamines as σ receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes. J. Med. Chem. 1992, 35, 4334-4343.
22. Krantz, A.; Spencer, R. W.; Tam, T. F.; Liak, T. J.; Copp, L. J.; Thomas, E. M.; Rafferty, S. P. Design and synthesis of 4H-1,3-benzoxazin-4-ones as potent alternate substrate inhibitors of human leukocyte elastase. J. Med. Chem. 1990, 33, 464-479.
23. Nakahara, H. Yamanouchi Pharmaceutical Co. Ltd. Unpublished results.
24. Skagerberg, B.; Bonelli, D.; Clementi, S.; Cruciani, G.; Ebert. Principal properties for aromatic substituents. A multivariate approach for design in QSAR. Quant. Struct.-Act. Relat. 1989, 8, 32-38.
25. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J. Physiol. 1991, 434, 23-40.
26. Difrancesco, D. Pacemaker mechanisms in cardiac tissue. Annu. Rev. Physiol. 1993, 55, 451-467.